Tyra Biosciences, Inc.

NASDAQ:TYRA

Biotechnology

Healthcare
$19.61 -2.48%

-$0.72 today

Market cap
$1.35B
Beta
0.75
P/E (TTM)
-13.4
EPS (TTM)
-$2.12
52W Low $8.98High $40.65

Volume 0.47M

Average 0.96M

TYRA Other Financing Activities

Financing cash flows not reported separately.

Tyra Biosciences, Inc.NASDAQ: TYRA

Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026

Other financing activities outflow grows to $0

Q1 FY2026 other financing activities was $0, compared with $0 a year earlier. Trailing-twelve-month other financing activities was $0.

Context

  • Other financing activities increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other financing activities holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMMar 2026
$0-100.0% YoY
Other Financing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Financing Activities history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Other Financing Activities vs competitors

How TYRA compares with its peers on the latest reported figures

  • TYRA's LTM Mar 2026 other financing activities of $0 is the 8th largest of the 11 companies compared; the peer median is $186.5K.
  • Its year-over-year change of -100.0% is the 7th highest of 10, against a peer median of -76.6%.
TYRA Competitors Peer median
Other Financing Activities for TYRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NUVBNuvation Bio Inc.LTM Jun 2026$207.2M +7785.3%—122.0%
MGNXMacroGenics, Inc.LTM Mar 2026$139.12M +52398.9%+394.4%88.6%
VSTMVerastem, Inc.LTM Mar 2026$8.3M -81.2%—16.7%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$1.61M ———
KURAKura Oncology, Inc.LTM Mar 2026$515K -76.6%—0.7%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$373K +108.4%——
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$297K -400.0%——
TYRATyra Biosciences, Inc.LTM Mar 2026$0 -100.0%——
JANXJanux Therapeutics, Inc.LTM Mar 2026$0 -100.0%—0.0%
BCAXBicara Therapeutics Inc. Common StockLTM Mar 2026$0 -100.0%——
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$0 +100.0%—0.0%
Peer median (excluding TYRA) $186.5K-76.6%+394.4%8.7%

Competitors are the stored peer set for TYRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(26.29M)(55.33M)(69.13M)(86.48M)(119.95M)
Depreciation & Amortization140K296K357K519K546K
Deferred Income Tax00000
Stock-Based Compensation2.89M10.59M13.53M22.8M28.01M
Change in Working Capital(481K)(5.85M)6.36M(729K)(1.63M)
Accounts Receivables00000
Inventory00000
Accounts Payables1.49M0000
Other Working Capital(1.97M)(5.85M)6.36M(729K)(1.63M)
Other Non-Cash Items3K3K(1.25M)(5.88M)(2.12M)
Operating Cash Flow(23.75M)(50.29M)(50.14M)(69.77M)(95.14M)
Capital Expenditures(661K)(559K)(770K)(664K)(141K)
Acquisitions (Net)16K0000
Purchases of Investments00(143.84M)(263.62M)(101.25M)
Sales of Investments000165.89M173.86M
Other Investing Activities160000
Investing Cash Flow(645K)(559K)(144.61M)(98.4M)72.46M
Debt Repayment(9K)0000
Common Stock Issued181.22M632K1.54M200M8.1M
Common Stock Repurchased000(420K)0
Dividends Paid00000
Other Financing Activities514K002.56M0
Financing Cash Flow311.35M632K1.54M202.14M8.1M
Effect of Forex Changes0(757K)000
Net Change in Cash286.96M(50.97M)(193.21M)33.96M(14.58M)
Free Cash Flow(24.41M)(50.84M)(50.91M)(70.44M)(95.28M)

Tyra Biosciences, Inc.

NASDAQ:TYRA

Intrinsic Alpha fair value

Locked

Current Price

$19.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.